Kiniksa Pharmaceuticals (KNSA) Competitors $27.74 +0.77 (+2.86%) Closing price 04:00 PM EasternExtended Trading$27.90 +0.16 (+0.58%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KNSA vs. SRPT, TLX, ADMA, BPMC, VRNA, NUVL, AXSM, GRFS, CYTK, and KRYSShould you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include Sarepta Therapeutics (SRPT), Telix Pharmaceuticals Limited American Depositary Shares (TLX), ADMA Biologics (ADMA), Blueprint Medicines (BPMC), Verona Pharma (VRNA), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Grifols (GRFS), Cytokinetics (CYTK), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Kiniksa Pharmaceuticals vs. Sarepta Therapeutics Telix Pharmaceuticals Limited American Depositary Shares ADMA Biologics Blueprint Medicines Verona Pharma Nuvalent Axsome Therapeutics Grifols Cytokinetics Krystal Biotech Sarepta Therapeutics (NASDAQ:SRPT) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation, community ranking and institutional ownership. Is SRPT or KNSA more profitable? Sarepta Therapeutics has a net margin of 7.43% compared to Kiniksa Pharmaceuticals' net margin of -2.36%. Sarepta Therapeutics' return on equity of 11.00% beat Kiniksa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Sarepta Therapeutics7.43% 11.00% 3.35% Kiniksa Pharmaceuticals -2.36%-7.31%-5.95% Does the MarketBeat Community prefer SRPT or KNSA? Sarepta Therapeutics received 1297 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 75.03% of users gave Sarepta Therapeutics an outperform vote while only 65.54% of users gave Kiniksa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSarepta TherapeuticsOutperform Votes147275.03% Underperform Votes49024.97% Kiniksa PharmaceuticalsOutperform Votes17565.54% Underperform Votes9234.46% Do analysts rate SRPT or KNSA? Sarepta Therapeutics currently has a consensus price target of $158.70, indicating a potential upside of 152.78%. Kiniksa Pharmaceuticals has a consensus price target of $38.00, indicating a potential upside of 36.99%. Given Sarepta Therapeutics' higher possible upside, research analysts clearly believe Sarepta Therapeutics is more favorable than Kiniksa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sarepta Therapeutics 0 Sell rating(s) 5 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.83Kiniksa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, SRPT or KNSA? Kiniksa Pharmaceuticals has lower revenue, but higher earnings than Sarepta Therapeutics. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSarepta Therapeutics$1.90B3.20-$535.98M$2.2827.54Kiniksa Pharmaceuticals$423.24M4.76$14.08M-$0.61-45.48 Does the media favor SRPT or KNSA? In the previous week, Kiniksa Pharmaceuticals had 6 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 22 mentions for Kiniksa Pharmaceuticals and 16 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.00 beat Kiniksa Pharmaceuticals' score of 0.80 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kiniksa Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has more risk and volatility, SRPT or KNSA? Sarepta Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Do insiders & institutionals have more ownership in SRPT or KNSA? 86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. 7.7% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummarySarepta Therapeutics beats Kiniksa Pharmaceuticals on 14 of the 19 factors compared between the two stocks. Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KNSA vs. The Competition Export to ExcelMetricKiniksa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.02B$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-198.137.3222.5118.54Price / Sales4.76241.49397.62103.34Price / CashN/A65.8538.1834.62Price / Book4.456.486.734.25Net Income$14.08M$143.41M$3.22B$248.18M7 Day Performance34.92%2.30%1.58%1.25%1 Month Performance27.42%7.14%4.05%3.76%1 Year Performance42.99%-2.61%15.75%5.28% Kiniksa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KNSAKiniksa Pharmaceuticals2.4929 of 5 stars$27.74+2.9%$38.00+37.0%+44.1%$2.02B$423.24M-198.13220Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeSRPTSarepta Therapeutics4.7413 of 5 stars$61.51+1.8%$158.70+158.0%-50.7%$5.97B$1.90B49.21840TLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.57-6.5%$22.00+25.2%N/A$5.94B$783.21M0.00N/AAnalyst RevisionNews CoverageHigh Trading VolumeADMAADMA Biologics1.4633 of 5 stars$24.51+12.1%$22.50-8.2%+265.0%$5.82B$426.45M87.54530Upcoming EarningsOptions VolumeNews CoveragePositive NewsGap UpHigh Trading VolumeBPMCBlueprint Medicines2.5642 of 5 stars$88.51+1.0%$124.53+40.7%-2.0%$5.66B$508.82M-81.95640Earnings ReportAnalyst ForecastNews CoveragePositive NewsVRNAVerona Pharma2.9073 of 5 stars$68.83+5.1%$78.50+14.0%+366.5%$5.56B$42.28M-35.8530Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsNUVLNuvalent1.8882 of 5 stars$75.20+2.3%$115.50+53.6%+11.4%$5.38BN/A-21.6740Upcoming EarningsPositive NewsAXSMAxsome Therapeutics4.8364 of 5 stars$107.24+0.9%$169.80+58.3%+52.2%$5.23B$385.69M-17.90380Upcoming EarningsAnalyst ForecastShort Interest ↓Positive NewsGRFSGrifols3.8946 of 5 stars$7.15-0.8%N/A+8.1%$4.92B$7.21B6.1126,300CYTKCytokinetics4.1759 of 5 stars$41.22+2.0%$79.13+92.0%-30.1%$4.91B$18.47M-7.66250Upcoming EarningsInsider TradeKRYSKrystal Biotech4.9058 of 5 stars$169.73+1.0%$222.71+31.2%+10.9%$4.90B$290.52M56.77210Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies Sarepta Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives ADMA Biologics Alternatives Blueprint Medicines Alternatives Verona Pharma Alternatives Nuvalent Alternatives Axsome Therapeutics Alternatives Grifols Alternatives Cytokinetics Alternatives Krystal Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KNSA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KNSA Stock Free KNSA Stock Alerts